0804 GMT - The results of AstraZeneca's upcoming cancer drug trial have the potential to drive consensus forecasts toward the drug maker's 2030 sales target of $80 billion, Berenberg analysts say in a note. The British pharma company expects positive key late-stage trial readouts for its breast cancer drug Datroway, label extensions for its breast cancer drug Enhertu and hypertension treatment baxdrostat. The company guides for high-single-digit revenue growth but should face headwinds from patent expiries, U.S. Medicare drug pricing reform and foreign currency effects, they say. AstraZeneca's share price is back on track after its 2025 outlook eased investor concerns about the prospects for its China business, which is hampered by ongoing corruption investigation against some of its employees. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 26, 2025 03:04 ET (08:04 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。